» Articles » PMID: 36499604

Complete Models of P53 Better Inform the Impact of Hotspot Mutations

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Dec 11
PMID 36499604
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in tumor suppressor genes often lead to cancerous phenotypes. Current treatments leverage signaling pathways that are often compromised by disease-derived deficiencies in tumor suppressors. P53 falls into this category as genetic mutations lead to physical changes in the protein that impact multiple cellular pathways. Here, we show the first complete structural models of mutated p53 to reveal how hotspot mutations physically deviate from the wild-type protein. We employed a recently determined structure for the p53 monomer to map seven frequent clinical mutations using computational modeling approaches. Results showed that missense mutations often changed the conformational structure of p53 in the DNA-binding site along with its electrostatic surface charges. We posit these changes may amplify the toxic effects of these hotspot mutations by destabilizing an important zinc ion coordination region in p53 to impede proper DNA interactions. These results highlight the imperative need for new studies on patient-derived proteins that may assist in redesigning structure-informed targeted therapies.

Citing Articles

Exploring the Functional Landscape of the p53 Regulatory Domain: The Stabilizing Role of Post-Translational Modifications.

Bakker M, Svensson O, So Rensen H, Skepo M J Chem Theory Comput. 2024; 20(14):5842-5853.

PMID: 38973087 PMC: 11270737. DOI: 10.1021/acs.jctc.4c00570.


Molecular Insights into Macromolecules Structure, Function, and Regulation.

Yang Z, Zhao J Int J Mol Sci. 2024; 25(10).

PMID: 38791335 PMC: 11121550. DOI: 10.3390/ijms25105296.

References
1.
Joerger A, Ang H, Fersht A . Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A. 2006; 103(41):15056-61. PMC: 1635156. DOI: 10.1073/pnas.0607286103. View

2.
Holch J, Stintzing S, Heinemann V . Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. Visc Med. 2016; 32(3):178-83. PMC: 4945779. DOI: 10.1159/000446052. View

3.
Bullock A, Henckel J, Fersht A . Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene. 2000; 19(10):1245-56. DOI: 10.1038/sj.onc.1203434. View

4.
Yin Y, Tainsky M, Bischoff F, Strong L, Wahl G . Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 1992; 70(6):937-48. DOI: 10.1016/0092-8674(92)90244-7. View

5.
Walker D, Bond J, Tarone R, Harris C, Makalowski W, Boguski M . Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene. 1999; 18(1):211-8. DOI: 10.1038/sj.onc.1202298. View